Literature DB >> 12429798

Circadian variation of topoisomerase II-alpha in human rectal crypt epithelium: implications for reduction of toxicity of chemotherapy.

Frederic Clayton1, Kathryn A Tessnow, John C Fang, Joseph A Holden, John G Moore.   

Abstract

Topoisomerase II-alpha is a target of common chemotherapeutic agents such as doxorubicin and etoposide, which induce DNA damage by altering the activity of this enzyme. We took rectal biopsies at 4-hour intervals over a 24-hour period (seven total) from each of 10 healthy volunteers and examined immunoperoxidase-stained coded anti-topoisomerase II-alpha-stained sections. A significant circadian periodicity was seen in the number of rectal crypt epithelial cell nuclei that were stained (P =.01). Mean peak staining was at 7:23 a.m. +/- 45 minutes, and the mean rate of change (difference between peak and trough expression) was 40%. Topoisomerase II-alpha expression in rectal epithelium has a significant circadian variation similar to that of tritiated thymidine incorporation. Although direct confirmation is needed, giving topoisomerase II-targeted chemotherapeutic agents at the proper time of day might reduce their mucositis side effects.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12429798     DOI: 10.1097/01.MP.0000032529.68297.B2

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  1 in total

Review 1.  New thoughts on the pathobiology of regimen-related mucosal injury.

Authors:  Lowell Anthony; Joanne Bowen; Adam Garden; Ian Hewson; Stephen Sonis
Journal:  Support Care Cancer       Date:  2006-04-01       Impact factor: 3.603

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.